Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beam Therapeutics (BEAM) Operating Margin: 2019-2025

Historic Operating Margin for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to -1,307.60%.

  • Beam Therapeutics' Operating Margin fell 56120.00% to -1,307.60% in Q3 2025 from the same period last year, while for Sep 2025 it was -837.12%, marking a year-over-year decrease of 78488.00%. This contributed to the annual value of -654.25% for FY2024, which is 60753.00% down from last year.
  • Beam Therapeutics' Operating Margin amounted to -1,307.60% in Q3 2025, which was up 7.86% from -1,419.22% recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Operating Margin peaked at 42.02% during Q4 2023, and registered a low of -3,339,550.00% during Q1 2021.
  • Over the past 3 years, Beam Therapeutics' median Operating Margin value was -746.40% (recorded in 2024), while the average stood at -836.66%.
  • In the last 5 years, Beam Therapeutics' Operating Margin crashed by 286,696,667bps in 2021 and then surged by 333,864,600bps in 2022.
  • Over the past 5 years, Beam Therapeutics' Operating Margin (Quarterly) stood at -124.31% in 2021, then plummeted by 31,979bps to -444.10% in 2022, then soared by 48,612bps to 42.02% in 2023, then slumped by 37,473bps to -332.71% in 2024, then tumbled by 56,120bps to -1,307.60% in 2025.
  • Its last three reported values are -1,307.60% in Q3 2025, -1,419.22% for Q2 2025, and -1,596.87% during Q1 2025.